Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: Alisertib|DRUG: Fulvestrant|OTHER: Laboratory Biomarker Analysis
Sponsor: Mayo Clinic
Collaborators: National Cancer Institute (NCI)